All AbMole products are for research use only, cannot be used for human consumption.
GDC-0879 is a potent and selective B-Raf kinase inhibitor with an EC50 of 0.75 µM. GDC-0879 has been used in various research studies for its anti-cancer properties. In GDC-0879-treated mice, both cell line- and patient-derived BRAFV600E tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared with mutant KRAS–expressing tumors.
 |
Source | Mol Cancer Ther (2016). Figure 2. GDC-0879 |
| Method | Western blots | |
| Cell Lines | BRAF WT, NRAS-mutant BRO melanoma cells | |
| Concentrations | 100, 1000, 10000 nmol/L | |
| Incubation Time | 24 h | |
| Results | In contrast, the tool compound GDC-0879 clearly induced formation of both CRAF/ARAF as well as CRAF/BRAF dimers. Nevertheless, BI 882370 induced phosphorylation of MEK1/2 and enhanced phosphorylation of ERK1/2 in BRO cells at concentrations between 3 and 300 nmol/L; importantly, however, expression of cyclins D1/D2 or Kip1/p27 was not affected |
| Cell Experiment | |
|---|---|
| Cell lines | A375 and Colo205 cells |
| Preparation method | GDC-0879 in vitro IC50 estimates for pMEK inhibition were determined using A375 and Colo205 cells. In brief, A375 or Colo205 cells were incubated with a range of GDC-0879 concentrations (from 0.5 nM to 6.75 μM) for 25 min. Cells were lysed, and the lysates were subjected to centrifugation at 16,100g for 30 min, and the level of total protein was determined using the Bradford method (Bradford, 1976). Enzyme-linked immunosorbent assay kits were used to determine pMEK1 and total MEK1 protein levels in a 96-well format (Tago Biosource International, Camarillo, CA). Samples were analyzed in duplicate at 20 μg of protein per well according to the protocol of the supplier. The optical densities obtained at 450 nm were converted to units per milliliter (for pMEK1) or nanograms per milliliter (for total MEK1) using a standard curve determined with recombinant pMEK1 or MEK1. The pMEK1/total MEK1 ratios were then calculated as units per nanogram. The IC50 estimates for pMEK1 inhibition were estimated by nonlinear regression using GraphPad Prism version 4.02 (GraphPad Software Inc., San Diego, CA). |
| Concentrations | 0.5 nM to 6.75 μM |
| Incubation time | 25 min |
| Animal Experiment | |
|---|---|
| Animal models | A375 and Colo205 tumor xenograft model |
| Formulation | 0.5% methylcellulose/0.2% Tween-80 (MCT) |
| Dosages | A375 xenograft: 50, 100, 200mg/kg once daily / Colo205 xenograft:50, 100 mg/kg once daily |
| Administration | oral gavage |
| Molecular Weight | 334.37 |
| Formula | C19H18N4O2 |
| CAS Number | 905281-76-7 |
| Solubility (25°C) | DMSO 47 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Raf Products |
|---|
| Sorafenib-d3
Sorafenib-d3 (Donafenib) is a deuterium-labeled Sorafenib, it is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. |
| XL-281
XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC50s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. |
| B-Raf IN 2
B-Raf IN 2 is a potent and selective BRAF inhibitor. |
| Brimarafenibum
Brimarafenibum (Brimarafenib) is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor, wtih antineoplastic effect. |
| Belvarafenib TFA
Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
